BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Cheap Stocks to Buy for High Returns in 2026. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released positive data from ongoing trials of VOXZOGO, which is the company’s approved treatment for achondroplasia.

​Achondroplasia is a genetic condition that causes dwarfism and stunted growth in children. The recent data reported by the company suggests that starting treatment before the age of 2 years maximizes benefits, including height gains, better body proportions, and arm span. The data showed that kids under 6 months, starting VOXZOGO, showed sustained improvements over 4 years.

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) noted that data suggest that more than 5,000 kids in 50+ countries have used VOXZOGO. Data from Japan, Europe, and the US suggest strong results. For instance, kids under 2 years in Japan gained 9.91 cm in 12 months, and 15.62 cm in 24 months.

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.